This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...
A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on ...
Hosted on MSN24d
Silexion reports breakthrough in KRAS cancer therapyThe drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...
A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations. The news was announced in a stock exchange filing ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback